tetano
Editor, Senior Moderator
Braz J Microbiol
. 2021 Apr 19.
doi: 10.1007/s42770-021-00498-z. Online ahead of print.
Comparative analysis of three point-of-care lateral flow immunoassays for detection of anti-SARS-CoV-2 antibodies: data from 100 healthcare workers in Brazil
Danielle Dias Conte[SUP] 1 [/SUP], Joseane Mayara Almeida Carvalho[SUP] 1 [/SUP], Luciano Kleber de Souza Luna[SUP] 2 3 [/SUP], Klinger Soares Fa?co-Filho[SUP] 1 [/SUP], Ana Helena Perosa[SUP] 4 [/SUP], Nancy Bellei[SUP] 1 [/SUP]
Affiliations
Abstract
Since the coronavirus disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard but requires a certified laboratory infrastructure with high-cost equipment and trained personnel. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) from S?o Paulo university hospital previously tested by RT-PCR: (1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), (2) Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China), and (3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days post symptoms (DPS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). The observed sensibility was 85.71%, 47.62%, and 44.05% for Bioclin, Wondfo, and Livzon, respectively, with a specificity of 100% for all LFIA. Bioclin was more sensitive (p<0.01), regardless of the DPS. Thus, the Bioclin may be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW.
Keywords: COVID-19; Healthcare workers; Lateral flow immunoassay; Point-of-care; SARS-CoV-2.
. 2021 Apr 19.
doi: 10.1007/s42770-021-00498-z. Online ahead of print.
Comparative analysis of three point-of-care lateral flow immunoassays for detection of anti-SARS-CoV-2 antibodies: data from 100 healthcare workers in Brazil
Danielle Dias Conte[SUP] 1 [/SUP], Joseane Mayara Almeida Carvalho[SUP] 1 [/SUP], Luciano Kleber de Souza Luna[SUP] 2 3 [/SUP], Klinger Soares Fa?co-Filho[SUP] 1 [/SUP], Ana Helena Perosa[SUP] 4 [/SUP], Nancy Bellei[SUP] 1 [/SUP]
Affiliations
- PMID: 33871824
- DOI: 10.1007/s42770-021-00498-z
Abstract
Since the coronavirus disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard but requires a certified laboratory infrastructure with high-cost equipment and trained personnel. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) from S?o Paulo university hospital previously tested by RT-PCR: (1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), (2) Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China), and (3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days post symptoms (DPS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). The observed sensibility was 85.71%, 47.62%, and 44.05% for Bioclin, Wondfo, and Livzon, respectively, with a specificity of 100% for all LFIA. Bioclin was more sensitive (p<0.01), regardless of the DPS. Thus, the Bioclin may be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW.
Keywords: COVID-19; Healthcare workers; Lateral flow immunoassay; Point-of-care; SARS-CoV-2.